Pacer WealthShield ETF PWS 深 沪
等待开盘 12-18 09:30:00 美东时间
32.7001
-0.030
-0.09%
华盛通- 最 高32.71
- 今 开32.71
- 成交量 2259股
- 最 低 32.675
- 昨 收 32.73
- 总市值 2779.51万
- 52周最高 33.71
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 28.5641
- 委 比 0.00%
- 总股本 85.00万
- 历史最高 33.71
- 量 比 0.15
- 振 幅 0.11%
- 历史最低 17.1301
- 每 手 1
- 风险率 1.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Reported Earlier: Aardvark Therapeutics Announces Alignment With The FDA On A Protocol Amendment To The Company's Phase 3 Hero Trial Of ARD-101 For The Treatment Of Hyperphagia Associated With Prader-Willi Syndrome
SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate
10-08 22:10
Acadia's Phase 3 COMPASS PWS Trial Of Intranasal Carbetocin Fails To Meet Primary Endpoint In Prader-Willi Hyperphagia
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in
09-24 19:02
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe
Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face market withdrawal.
08-16 01:30
凯雷Q2继续重仓航空维修巨头StandardAero(SARO.US) 清仓文远知行(WRD.US)
全球另类资产管理巨头凯雷(CARLYLE GROUP INC)递交了截止至2025年6月30日的第二季度持仓报告(13F)。
08-13 18:47
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardv...
07-18 20:00
3M Reports Second-Quarter 2025 Results, Increases Full-Year EPS Guidance
GAAP sales of $6.3 billion, up 1.4%; operating margin 18.0%, down (230) bps; EPS of $1.34, down 38%, all YoY Adjusted sales of $6.2 billion with organic growth of 1.5% YoY Adjusted operating...
07-18 18:30
Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress
Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February.
07-01 02:06
